Trevi CEO awarded options on 675,000 shares

Trevi Therapeutics, Inc. reported that President and CEO Jennifer L. Good received a grant of stock options covering 675,000 shares of common stock.

Rhea-AI Filing Summary

Trevi Therapeutics, Inc. reported that President and CEO Jennifer L. Good received a grant of stock options covering 675,000 shares of common stock. The award was granted on February 19, 2026 at no cost on grant and represents a compensation-related acquisition, not an open-market purchase.

The 675,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, so long as she continues her service with the company. This structure ties the potential ownership benefit to her ongoing tenure over the multi-year vesting period.

Insider Trade Summary

Grant/Award: 675,000 shares

Grant/Award 1 txn

Insider GOOD JENNIFER L

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	675,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 675,000 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

FAQ

What insider transaction did Trevi Therapeutics (TRVI) report for its CEO?

Trevi Therapeutics reported a stock option grant to President and CEO Jennifer L. Good for 675,000 shares. The award is part of her compensation and represents an acquisition of derivative securities, not an open-market stock purchase.

How many Trevi Therapeutics (TRVI) shares are covered by the new CEO option grant?

The reported stock option grant to Trevi Therapeutics CEO Jennifer L. Good covers 675,000 shares of common stock. These are underlying shares for options, meaning they can potentially be acquired upon future exercise, subject to the vesting schedule.

What is the vesting schedule for the Trevi Therapeutics (TRVI) CEO option grant?

The 675,000-share option grant to Trevi Therapeutics CEO Jennifer L. Good is scheduled to vest in equal monthly installments through February 19, 2030. Vesting depends on her continued service with the company over that multi-year period.

Did the Trevi Therapeutics (TRVI) CEO buy shares on the open market in this Form 4?

No, the Form 4 reports a grant of stock options to CEO Jennifer L. Good, not an open-market share purchase. The transaction is coded as a grant or award acquisition of derivative securities rather than a market trade.

What transaction code is used for the Trevi Therapeutics (TRVI) CEO option grant?

The option grant to Trevi Therapeutics CEO Jennifer L. Good uses transaction code "A" for grant, award, or other acquisition. This indicates the options were awarded as part of compensation, with no sale or open-market purchase involved.

Over what period will the Trevi Therapeutics (TRVI) CEO’s options fully vest?

The CEO’s 675,000-share option grant is set to vest in equal monthly installments through February 19, 2030. Full vesting therefore occurs over approximately four years from the February 19, 2026 grant date, assuming continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOOD JENNIFER L

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.56	02/19/2026		A		675,000		(1)	02/18/2036	Common Stock	675,000	$0	675,000	D

Explanation of Responses:

1. This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

	/s/ Christopher Galletta, attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.